drugset / Trial / NCT05539729

Vancomycin Study in Multiple Sclerosis (MS)

NCT05539729

RandomizedParallel-groupTriple-blindTreatment

Summary

The overall goal of this study is to elucidate a mechanism by which vancomycin modulates the gut-brain axis in multiple sclerosis (MS). The gut microbiome plays an important role in autoimmunity, including MS. However, the identity of gut microbes modulating neuroinflammation in MS and their mechanisms of action remain obscure. Hence, here the research team proposes to investigate the effects of vancomycin on the gut microbiota composition, peripheral immune function, and brain MRI lesions in MS patients.

Timeline

Start
2023-01-31
Primary completion
2026-03
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Vancomycin Other / unclassified 125 mg Oral

Indications